James Roosevelt Jr

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR

News

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks